Binds Enzyme Patents (Class 424/146.1)
  • Patent number: 10428159
    Abstract: Provided herein are monoclonal antibodies that recognize, bind to, and block interactions of other molecules with AGR2 and C4.4A. Also provided herein are methods of using anti-AGR2 and anti-C4.4A antibodies to treat cancer.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: October 1, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Craig D. Logsdon, Vijaya Ramachandran, Thiruvengadam Arumugam
  • Patent number: 10317401
    Abstract: Provided herein are methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis and other proteinuric renal diseases such as native FSGS, minimal change disease, glomerular nephritis, membrano-proliferative glomerular nephritis (membranous), or IgA glomerular nephritis (membranous).
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: June 11, 2019
    Inventor: Minnie Sarwal
  • Patent number: 10285959
    Abstract: The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: May 14, 2019
    Assignee: TopoTarget UK Limited
    Inventors: Henri Lichenstein, Mike Jeffers, Xiaozhang Qian, Maxwell Sehested, Kamille Dumong Erichsen, James Ritchie
  • Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10202430
    Abstract: Materials and methods for using multivalent molecules (e.g., antibodies) to modulate cellular function. A molecule can be targeted to a particular type of cell, either through direct binding to an epitope on the surface of the cell, or through a linker that recognizes both the multivalent molecule and a marker on the cell surface. The invention provides a chimeric polypeptide comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence comprises an WIC Class I peptide sequence, and where the second amino acid sequence comprises an epitope to which a multivalent molecule binds, including wherein the multivalent molecule is an IgM antibody, including antibody hIgM22. The invention provides a linker molecule for targeting IgM antibody, including antibody hIgM22, to a cell in the oligodendrocyte lineage.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: February 12, 2019
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Larry R. Pease, Moses Rodriguez
  • Patent number: 10143747
    Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: December 4, 2018
    Assignee: IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef Penninger, Daniel Schramek
  • Patent number: 10107821
    Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: October 23, 2018
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
  • Patent number: 10092548
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases.
    Type: Grant
    Filed: July 19, 2014
    Date of Patent: October 9, 2018
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ho Jeong Kwon, Nam Hee Kim
  • Patent number: 10058558
    Abstract: The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: August 28, 2018
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Soon Im Lee, Yeon Jung Song, Min Jae Shin, Kook Hwan Oh, Kyung Don Ju, Eun Kyoung Shin, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Min Jeong Kim, Hye Soun Eum
  • Patent number: 9949956
    Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: April 24, 2018
    Assignee: Aerpio Therapeutics, Inc.
    Inventors: Robert Shalwitz, Kevin Gene Peters
  • Patent number: 9920122
    Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: March 20, 2018
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventor: Timo Kars van den Berg
  • Patent number: 9884918
    Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 6, 2018
    Assignee: Nestec S.A.
    Inventor: Nicholas Chi-Kwan Ling
  • Patent number: 9834582
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: December 5, 2017
    Assignee: New York University
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Patent number: 9777056
    Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: October 3, 2017
    Assignee: New York University
    Inventors: Einar M. Sigurdsson, Ayodeji Asuni
  • Patent number: 9771431
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: September 26, 2017
    Assignee: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • Patent number: 9745347
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 29, 2017
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel Bar-Shavit
  • Patent number: 9625459
    Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: April 18, 2017
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
  • Patent number: 9610326
    Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an amyloid beta peptide, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 4, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lawrence Steinman, Jacqueline Grant
  • Patent number: 9547010
    Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: January 17, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Essig, Wolfgang Hoesel, Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Patent number: 9540431
    Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: January 10, 2017
    Assignee: Apogenix AG
    Inventors: Harald Fricke, Michaela Fontenay, Claudia Kunz
  • Patent number: 9523692
    Abstract: The invention provides populations of molecules that are prepared as, or treated to become, homogeneous for one or more molecular characteristics. In an aspect, the invention relates to molecular weight standards that may be used to determine the molecular weight or apparent molecular weight of uncharacterized molecules, such as proteins and nucleic acids, as well as in other applications. In one aspect, the molecular weight standards are pre-stained.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: December 20, 2016
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Joseph W. Amshey, Roumen A. Bogoev
  • Patent number: 9504696
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
  • Patent number: 9486471
    Abstract: Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: November 8, 2016
    Assignee: McMaster University
    Inventors: Mickie Bhatia, Eleftherios Sachlos
  • Patent number: 9458227
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: October 4, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Patent number: 9428563
    Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: August 30, 2016
    Assignee: Alkermes, Inc.
    Inventor: Juan Alvarez
  • Patent number: 9422564
    Abstract: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: August 23, 2016
    Assignee: Dynavax Technologies Corporation
    Inventors: Dino Dina, Karen L. Fearon, Jason Marshall
  • Patent number: 9408910
    Abstract: The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: August 9, 2016
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ju-Hee Ryu, Kwang-Meyung Kim, Ick-Chan Kwon, Kui-Won Choi, Sang-Yoon Kim, Beom-Suk Lee, Dae-Yoon Chi, Hee-Seup Kil, Hyun-Ju Sung
  • Patent number: 9289447
    Abstract: Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 22, 2016
    Assignee: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Alison Kay Holzer
  • Patent number: 9168299
    Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: October 27, 2015
    Assignee: LIPUM AB
    Inventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
  • Patent number: 9132174
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 15, 2015
    Assignee: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S Kapiloff, Jinliang Li, Michael Kritzer, Catherine Passariello, Kimberly Dodge-Kafka
  • Patent number: 9090932
    Abstract: Disclosed are a highly safe treatment method for hyperlipidemia and a therapeutic agent for hyperlipidemia. Specifically, the invention provides a novel method for screening an agent for treating hyperlipidemia, more specifically, a method for screening a substance that can inhibit the production or function of gangliosides, particularly GM3, or inhibit the activity or expression of GM3 synthase to reduce a blood lipid level. A pharmaceutical composition, which can specifically inhibit the production of gangliosides, particularly GM3, thereby effective for hyperlipidemia treatment, and others are also provided.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: July 28, 2015
    Assignee: Japan Science and Technology Agency
    Inventors: Jinichi Inokuchi, Masakazu Nagafuku, Hirotaka Hayamizu
  • Patent number: 9072737
    Abstract: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: July 7, 2015
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Abd Higazi, Nuha Hijazi
  • Publication number: 20150147338
    Abstract: Aspects of the invention provide methods for treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate for the treatment of a disease associated with elevated iNOS including autoimmune, chronic inflammatory, neurodegenerative, or cardiovascular diseases.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Inventors: Peter G. Traber, Eliezer Zomer, Anatole A. Klyosov
  • Patent number: 9040052
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: May 26, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Patent number: 9034332
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: May 19, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9034331
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: May 19, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Publication number: 20150132317
    Abstract: Methods and compositions for treating neuroblastoma are disclosed.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 14, 2015
    Inventors: Yael P. Mosse, Erica L. Carpenter
  • Patent number: 9028825
    Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: May 12, 2015
    Assignee: Universite de Geneve
    Inventors: Denis Francois Hochstrasser, Jean-Charles Sanchez
  • Patent number: 9023359
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: May 5, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9017681
    Abstract: The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: April 28, 2015
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Lonny Levin, Jochen Buck, Leo Brizuela, Michael Pinnisi
  • Publication number: 20150110802
    Abstract: Methods are provided for producing a plurality of antibody species in a single animal, comprising delivering a plurality of antigen species to a single animal, where each antigen species is delivered to the animal at an anatomically distinct location. Also provided are methods for generating an immune response in an animal, where each antigen species is delivered to the animal at an anatomically distinct location, under conditions in which the animal produces a plurality of antibody species, where each antibody species specifically binds to a different antigen species among the plurality of antigen species.
    Type: Application
    Filed: February 26, 2013
    Publication date: April 23, 2015
    Applicant: Medlmmune, LLC
    Inventors: Partha S. Chowdhury, Chew-Shun Chang
  • Publication number: 20150098938
    Abstract: Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 9, 2015
    Applicant: The Penn State Research Foundation
    Inventor: Yuguang Shi
  • Patent number: 9000132
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 7, 2015
    Assignee: diaDexus, Inc.
    Inventors: Paul Levi Miller, Laura Corral
  • Patent number: 8999325
    Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: April 7, 2015
    Assignee: Aerpio Therapeutics, Inc
    Inventors: Kevin Peters, Robert Shalwitz
  • Patent number: 8999341
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: April 7, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 8992927
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: March 31, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 8986929
    Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: March 24, 2015
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Bernard Lerer, Lior Greenbaum
  • Patent number: 8986694
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: March 24, 2015
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Publication number: 20150064134
    Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Cynthia Lander, Colleen Brophy